Submit a utility to the registry.

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Viewing 1 - 10 of 44 results
Title   Year(s) of data collection   Valuation Method   Country   Condition  
Selection of autoimmune disease health state utilities (Armuzzi A et al., BMC Gastroenterol. 2023. doi:10.1186/s12876-023-02640-7) 2020 - 2021 EQ-5D-5L France, Germany, Italy, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America Ulcerative colitis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
a point-in-time survey of 164 matched patients treated with tofacitinib
Title
Selection of autoimmune disease health state utilities (Schreiber S et al., J Crohns Colitis. 2023. doi:10.1093/ecco-jcc/jjad018)
Year(s) of data collection
2017 - 2018
Valuation Method
EQ-5D
Country
Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea (Republic of), Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Ukraine, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Ulcerative colitis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
An RCT for filgotinib in 786 adults with moderately to severely active UC
Title
Selection of orthopedic and musculoskeletal health state utilities (Hustedt JW et al., J Hand Surg Am. 2023. doi:10.1016/j.jhsa.2022.11.021)
Year(s) of data collection
2020 - 2021
Valuation Method
EQ-5D
Country
United States of America
Condition
Thumb carpometacarpal arthritis
DOI
10.7910/DVN/VR4XYO
Author(s)
Registry, Utilities
Description
Health state utilities for orthopedic and musculoskeletal conditions
Sample Characteristics
A prospective clinical trial of 48 participants comparing denervation with suspension arthroplasty for treatment of carpometacarpal arthritis of the thumb
Title
Selection of oncology health state utilities (Clavo B et al., Int J Environ Res Public Health. 2023. doi:10.3390/ijerph20021479)
Year(s) of data collection
2019 - 2022
Valuation Method
EQ-5D-5L
Country
Spain
Condition
Symptomatic Cancer Survivor
DOI
10.7910/DVN/L4V2LU
Author(s)
Registry, Utilities
Description
Health state utilities for oncology conditions
Sample Characteristics
26 patients with persistent or refractory side effects of cancer treatments to investigate the effects of ozone treatment
Title
Selection of neurological disease health state utilities (Looby A et al., J Med Econ. 2023. doi:10.1080/13696998.2023.2189395)
Year(s) of data collection
2022
Valuation Method
EQ-5D-5L
Country
United Kingdom of Great Britain and Northern Ireland
Condition
Spinal cord injury
DOI
10.7910/DVN/VJSSSX
Author(s)
Registry, Utilities
Description
Health state utilities for neurological disease conditions
Sample Characteristics
A cohort of 57 patients with spinal cord injury
Title
Selection of neurological disease health state utilities (Lacy B et al., Clin Park Relat Disord. 2023. doi:10.1016/j.prdoa.2022.100180)
Year(s) of data collection
2010 - 2011
Valuation Method
EQ-5D
Country
United States of America
Condition
Parkinson's disease
DOI
10.7910/DVN/VJSSSX
Author(s)
Registry, Utilities
Description
Health state utilities for neurological disease conditions
Sample Characteristics
A cross-sectional study of 124 patients with PD at an academic movement clinic
Title
Selection of orthopedic and musculoskeletal health state utilities (Zhou AK et al., Eur J Orthop Surg Traumatol. 2023. doi:10.1007/s00590-022-03204-3)
Year(s) of data collection
2014 - 2021
Valuation Method
EQ-5D-5L
Country
United Kingdom of Great Britain and Northern Ireland
Condition
Open talus fractures
DOI
10.7910/DVN/VR4XYO
Author(s)
Registry, Utilities
Description
Health state utilities for orthopedic and musculoskeletal conditions
Sample Characteristics
14 participants from the review of electronic hospital records, cohort
Title
Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)
Year(s) of data collection
2018 - 2020
Valuation Method
EQ-5D-5L
Country
Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Myasthenia gravis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title
Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)
Year(s) of data collection
2021
Valuation Method
EQ-5D-5L, HUI3
Country
Belgium, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Myasthenia gravis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
9000 participants in the general population norms study that included adult patients with gMG randomly assigned to treatment with efgartigimod or conventional therapy
Title
Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)
Year(s) of data collection
2019 - 2022
Valuation Method
EQ-5D-5L, HUI3
Country
Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Myasthenia gravis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
1299 participants (EQ-5D-5L) and 549 participants (HUI3) from MyRealWorld-MG study